Cemex Sells Guatemalan Operations to Holcim for $200 Million
By Anthony Harrup
MEXICO CITY--Mexican building materials company Cemex sold its operations in Guatemala to Holcim Group for around $200 million as it continues to reshape its portfolio with a focus on developed markets.
The Guatemalan assets include a grinding mill with capacity of 600,000 metric tons a year, three ready-mix concrete plants, and five distribution centers, Cemex said Tuesday.
Cemex said its announced sales this year amount to more than $2 billion of assets located mostly in emerging markets. It will deploy the proceeds in developed markets, primarily the U.S., with a focus on aggregates, cement and urbanization solutions.
The strategy is concentrated on markets where Cemex already has operations and the most promising growth opportunities, the company added.
In August, Cemex agreed to sell its operations in the Dominican Republic to Cementos Progreso Holdings for around $950 million. Last week, it said it expects to receive $209 million from the sale of its 34.8% stake in technology consultancy company Neoris. Cemex reached a deal in April to sell its operations in the Philippines.
Write to Anthony Harrup at anthony.harrup@wsj.com
(END) Dow Jones Newswires
September 10, 2024 18:03 ET (22:03 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks